Table 2.

Association between lowering low-density lipoprotein cholesterol (LDL-C) to clinically recommended levels and CV outcomes for each cohort.

Group/Independent VariableHR (95% CI)p
RA Plus General Controls, n = 8033
  RA (vs controls)1.76 (1.43–2.17)< 0.0001
  Lowered LDL-C (vs not lowered)0.71 (0.57–0.89)0.003
  Age1.07 (1.06–1.08)< 0.0001
  Male sex (vs female)1.34 (1.10–1.64)0.004
  HTN (yes vs no)1.41 (1.03–1.64)0.031
  Anti-HTN medications (yes vs no)1.45 (0.96–2.20)0.078
  Smoker (vs nonsmoker)1.53 (1.10–2.13)0.011
  Unknown smoking status (vs nonsmoker)1.21 (0.88–1.68)0.248
  Diabetes (yes vs no)1.56 (1.28–1.90)< 0.0001
  Interaction term of RA × lowered LDL-C0.852
RA Plus OA Controls, n = 4300
  RA (vs controls)1.13 (0.92–1.40)0.245
  Lowered LDL-C (vs not lowered)0.50 (0.43–0.58)< 0.0001
  Age1.06 (1.05–1.07)< 0.0001
  Male sex (vs female)1.30 (1.04–1.64)0.024
  HTN (yes vs no)1.32 (0.93–1.88)0.125
  Anti-HTN medications (yes vs no)1.58 (1.00–2.48)0.049
  Smoker (vs nonsmoker)1.61 (1.12–2.32)0.011
  Unknown smoking status (vs nonsmoker)0.92 (0.61–1.40)0.698
  Diabetes (yes vs no)1.32 (1.07–1.64)0.011
  Interaction term of RA × lowered LDL-C0.610
  • CV: cardiovascular; RA: rheumatoid arthritis; OA: osteoarthritis; HTN: hypertension.